US Patent Issued to AKSTON BIOSCIENCES on April 21 for "Ultra-long acting insulin-Fc fusion proteins and methods of use" (Massachusetts Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,605, issued on April 21, was assigned to AKSTON BIOSCIENCES Corp. (Beverly, Mass.).

"Ultra-long acting insulin-Fc fusion proteins and methods of use" was invented by Thomas M. Lancaster (Wenham, Mass.) and Todd C. Zion (Salem, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods for lowering the blood glucose of a target subject, including for treating diabetes, by administering recombinantly manufactured ultra-long acting insulin-Fc fusion proteins."

The patent was filed on Jan. 10, 2023, under Application No. 18/152,595.

*For further information, including images, charts and tables, please visit: http://p...